---
document_datetime: 2026-02-05 15:02:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lyxumia.html
document_name: lyxumia.html
version: success
processing_time: 0.0641308
conversion_datetime: 2026-02-09 21:57:02.987488
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Academia](/en/partners-networks/academia)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One substance - one assessment](/en/partners-networks/one-substance-one-assessment-osoa-eu-collaboration-chemicals-related-data)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Lyxumia

# Lyxumia

[RSS](/en/individual-human-medicine.xml/66402)

##### Withdrawn

This medicine's authorisation has been withdrawn

lixisenatide Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Lyxumia](#news-on)
- [More information on Lyxumia](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 December 2025, the European Commission withdrew the marketing authorisation for Lyxumia (lixisenatide) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanofi Winthrop Industrie, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Lyxumia was granted marketing authorisation in the EU on 1 February 2013 for treatment of type 2 diabetes. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity on 18 September 2017.

Lyxumia is GLP-1 receptor agonist. There are therapeutic alternatives such as other GLP-1 receptor agonists authorised and available throughout the EU for the treatment of type 2 diabetes.

Lyxumia : EPAR - Summary for the public

English (EN) (87.95 KB - PDF)

**First published:** 14/03/2013

**Last updated:** 05/02/2026

[View](/en/documents/overview/lyxumia-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-332)

български (BG) (122.14 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/bg/documents/overview/lyxumia-epar-summary-public_bg.pdf)

español (ES) (112.29 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/es/documents/overview/lyxumia-epar-summary-public_es.pdf)

čeština (CS) (116.51 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/cs/documents/overview/lyxumia-epar-summary-public_cs.pdf)

dansk (DA) (89.53 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/da/documents/overview/lyxumia-epar-summary-public_da.pdf)

Deutsch (DE) (90.72 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/de/documents/overview/lyxumia-epar-summary-public_de.pdf)

eesti keel (ET) (87.26 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/et/documents/overview/lyxumia-epar-summary-public_et.pdf)

ελληνικά (EL) (121.46 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/el/documents/overview/lyxumia-epar-summary-public_el.pdf)

français (FR) (111.89 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/fr/documents/overview/lyxumia-epar-summary-public_fr.pdf)

hrvatski (HR) (110.71 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/hr/documents/overview/lyxumia-epar-summary-public_hr.pdf)

italiano (IT) (86.98 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/it/documents/overview/lyxumia-epar-summary-public_it.pdf)

latviešu valoda (LV) (115.16 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/lv/documents/overview/lyxumia-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (113.53 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/lt/documents/overview/lyxumia-epar-summary-public_lt.pdf)

magyar (HU) (108.27 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/hu/documents/overview/lyxumia-epar-summary-public_hu.pdf)

Malti (MT) (118.69 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/mt/documents/overview/lyxumia-epar-summary-public_mt.pdf)

Nederlands (NL) (88.39 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/nl/documents/overview/lyxumia-epar-summary-public_nl.pdf)

polski (PL) (116.16 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/pl/documents/overview/lyxumia-epar-summary-public_pl.pdf)

português (PT) (88.22 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/pt/documents/overview/lyxumia-epar-summary-public_pt.pdf)

română (RO) (112.67 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/ro/documents/overview/lyxumia-epar-summary-public_ro.pdf)

slovenčina (SK) (113.36 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sk/documents/overview/lyxumia-epar-summary-public_sk.pdf)

slovenščina (SL) (109.69 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sl/documents/overview/lyxumia-epar-summary-public_sl.pdf)

Suomi (FI) (86.74 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/fi/documents/overview/lyxumia-epar-summary-public_fi.pdf)

svenska (SV) (89.13 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sv/documents/overview/lyxumia-epar-summary-public_sv.pdf)

Lyxumia : EPAR - Risk-management-plan summary

English (EN) (119.56 KB - PDF)

**First published:** 18/01/2021

**Last updated:** 05/02/2026

[View](/en/documents/rmp-summary/lyxumia-epar-risk-management-plan-summary_en.pdf)

## Product information

Lyxumia : EPAR - Product Information

English (EN) (1.01 MB - PDF)

**First published:** 14/03/2013

**Last updated:** 05/02/2026

[View](/en/documents/product-information/lyxumia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-213)

български (BG) (1.53 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/bg/documents/product-information/lyxumia-epar-product-information_bg.pdf)

español (ES) (1.61 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/es/documents/product-information/lyxumia-epar-product-information_es.pdf)

čeština (CS) (1.6 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/cs/documents/product-information/lyxumia-epar-product-information_cs.pdf)

dansk (DA) (1.35 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/da/documents/product-information/lyxumia-epar-product-information_da.pdf)

Deutsch (DE) (1.37 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/de/documents/product-information/lyxumia-epar-product-information_de.pdf)

eesti keel (ET) (1.41 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/et/documents/product-information/lyxumia-epar-product-information_et.pdf)

ελληνικά (EL) (1.61 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/el/documents/product-information/lyxumia-epar-product-information_el.pdf)

français (FR) (2.41 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/fr/documents/product-information/lyxumia-epar-product-information_fr.pdf)

hrvatski (HR) (2.3 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/hr/documents/product-information/lyxumia-epar-product-information_hr.pdf)

íslenska (IS) (2.19 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/is/documents/product-information/lyxumia-epar-product-information_is.pdf)

italiano (IT) (2.28 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/it/documents/product-information/lyxumia-epar-product-information_it.pdf)

latviešu valoda (LV) (2.56 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/lv/documents/product-information/lyxumia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.24 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/lt/documents/product-information/lyxumia-epar-product-information_lt.pdf)

magyar (HU) (2.4 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/hu/documents/product-information/lyxumia-epar-product-information_hu.pdf)

Malti (MT) (1.41 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/mt/documents/product-information/lyxumia-epar-product-information_mt.pdf)

Nederlands (NL) (2.83 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/nl/documents/product-information/lyxumia-epar-product-information_nl.pdf)

norsk (NO) (2.71 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/no/documents/product-information/lyxumia-epar-product-information_no.pdf)

polski (PL) (2.43 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/pl/documents/product-information/lyxumia-epar-product-information_pl.pdf)

português (PT) (2.36 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/pt/documents/product-information/lyxumia-epar-product-information_pt.pdf)

română (RO) (2.54 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/ro/documents/product-information/lyxumia-epar-product-information_ro.pdf)

slovenčina (SK) (2.41 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sk/documents/product-information/lyxumia-epar-product-information_sk.pdf)

slovenščina (SL) (3.07 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sl/documents/product-information/lyxumia-epar-product-information_sl.pdf)

Suomi (FI) (2.57 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/fi/documents/product-information/lyxumia-epar-product-information_fi.pdf)

svenska (SV) (2.54 MB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sv/documents/product-information/lyxumia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000223999 27/08/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lyxumia  : EPAR - All Authorised presentations

English (EN) (59.53 KB - PDF)

**First published:** 14/03/2013

**Last updated:** 05/02/2026

[View](/en/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-48)

български (BG) (82.35 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/bg/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_bg.pdf)

español (ES) (47.25 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/es/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (59.56 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/cs/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (49.94 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/da/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.87 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/de/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.64 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/et/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (92.15 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/el/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_el.pdf)

français (FR) (47.38 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/fr/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (69.05 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/hr/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/is/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (68.31 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/it/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.24 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/lv/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (65.05 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/lt/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (58.13 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/hu/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (59.74 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/mt/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (51.43 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/nl/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (60.93 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/no/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.47 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/pl/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.34 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/pt/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_pt.pdf)

română (RO) (70.55 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/ro/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (71.44 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sk/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (64.74 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sl/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.07 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/fi/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.99 KB - PDF)

**First published:**

14/03/2013

**Last updated:**

05/02/2026

[View](/sv/documents/all-authorised-presentations/lyxumia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lyxumia Active substance lixisenatide International non-proprietary name (INN) or common name lixisenatide Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BJ03

### Pharmacotherapeutic group

- Drugs used in diabetes
- Glucagon-like peptide-1 (GLP-1) analogues

### Therapeutic indication

Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

## Authorisation details

EMA product number EMEA/H/C/002445 Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail

Opinion adopted 15/11/2012 Marketing authorisation issued 31/01/2013 Withdrawal of marketing authorisation 18/12/2025 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lyxumia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (157.39 KB - PDF)

**First published:** 05/09/2024

**Last updated:** 05/02/2026

[View](/en/documents/procedural-steps-after/lyxumia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Lyxumia  : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (230.62 KB - PDF)

**First published:** 28/11/2013

**Last updated:** 05/02/2026

[View](/en/documents/procedural-steps-after/lyxumia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Lyxumia  : EPAR - Public assessment report

English (EN) (1.64 MB - PDF)

**First published:** 14/03/2013

**Last updated:** 05/02/2026

[View](/en/documents/assessment-report/lyxumia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lyxumia

Adopted

Reference Number: EMA/CHMP/706420/2012

English (EN) (69.75 KB - PDF)

**First published:** 16/11/2012

**Last updated:** 05/02/2026

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lyxumia_en.pdf)

#### News on Lyxumia

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[EMA statement on ongoing review of GLP-1 receptor agonists](/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists) 11/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Investigation into GLP-1-based diabetes therapies concluded](/en/news/investigation-glp-1-based-diabetes-therapies-concluded) 26/07/2013

[European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes](/en/news/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes) 26/03/2013

#### More information on Lyxumia

- [EMEA-000916-PIP01-10-M07 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000916-pip01-10-m07)
- [Programme of Epidemiological Studies of Lixisenatide and other GLP-1 Receptor Agonists - post-authorisation study](https://catalogues.ema.europa.eu/study/19786)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 05/02/2026

## Share this page

[Back to top](#main-content)